Chardan acts as lead left bookrunner in femasys' $34.45 million ipo

New york, june 21, 2021 /prnewswire/ -- chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the $34.45 million ipo of femasys, inc. (nasdaq: femy) a biomedical company focused on transforming women's healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. "we are delighted to work with the outstanding team at femasys in support of their commitment to women's healthcare," said matthew mrozinski, a partner in the investment banking group at chardan.
FEMY Ratings Summary
FEMY Quant Ranking